One study demonstrated the therapeutic potential of a hybrid cytokine with active domains of IL-2 and IL-33 that induced the remission of lupus-mediated GN in NZM2328 and MRL/lpr mice.41 The remission was accompanied by the persistent elevation of Tregs in renal lymph nodes. This evidence concerns the gene IL33 and systemic lupus erythematosus.